NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).

被引：43
|
作者：
Slamon, Dennis J.
Fasching, Peter A.
Patel, Ravindranath
Verma, Sunil
Hurvitz, Sara A.
Chia, Stephen K. L.
Crown, John
Martin, Miguel
Barrios, Carlos H.
Spera, Gonzalo
Lopez, Celine
Hor, Ines
Pelov, Diana
Hughes, Gareth
Nawinne, Moditha
Hortobagyi, Gabriel N.
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Hosp Erlangen, Erlangen, Germany
[3] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[5] BC Canc Agcy, Vancouver, BC, Canada
[6] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland
[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
[8] Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil
[9] Translat Res Oncol, Montevideo, Uruguay
[10] Translat Res Oncol TRIO, Paris, France
[11] Novartis Pharmaceut, E Hanover, NJ USA
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharma AG, Basil, Switzerland
[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS597
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Ribociclib plus letrozole in male patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2negative (HER2-) advanced breast cancer (ABC): Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Campone, Mario
    De Laurentiis, Michelino
    Zamagni, Claudio
    Kudryavcev, Igor
    Agterof, Mariette
    Brown-Glaberman, Ursa
    Palacova, Marketa
    Chatterjee, Sanjoy
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Martin, Miguel
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
    Inoue, Kenichi
    Masuda, Norikazu
    Iwata, Hiroji
    Takahashi, Masato
    Ito, Yoshinori
    Miyoshi, Yasuo
    Nakayama, Takahiro
    Mukai, Hirofumi
    van der Walt, Jan-Stefan
    Mori, Joji
    Sakaguchi, Sachi
    Kawaguchi, Tsutomu
    Tanizawa, Yoshinori
    Llombart-Cussac, Antonio
    Sledge, George W., Jr.
    Toi, Masakazu
    BREAST CANCER, 2021, 28 (05) : 1038 - 1050
  • [33] CompLEEment-1: phase 3b study of ribociclib 1 letrozole for the treatment of hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
    Zamagni, C.
    Martin, M.
    Ring, A.
    Cottu, P.
    Zhou, K.
    Wu, J.
    Zarate, J. P.
    De Laurentiis, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
    Zhao, Hongmeng
    Li, Dan
    Li, Qian
    Zhang, Bin
    Xiao, Chunhua
    Zhao, Ying
    Ge, Jie
    Yu, Yue
    Jia, Yumian
    Guo, Xiaojing
    Cao, Xuchen
    Wang, Xin
    ONCOLOGIST, 2024, 29 (06): : e763 - e770
  • [35] Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) receiving ribociclib (RIB) plus endocrine therapy (ET)
    Yap, Y. S.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Kim, S. J.
    Aruga, T.
    Toyama, T.
    Saeki, T.
    Yamanaka, T.
    Saito, M.
    Watanabe, J.
    Takahashi, M.
    Nakamura, S.
    Inoue, K.
    Suarez-Vizcarra, J.
    He, W.
    Solovieff, N.
    Su, F.
    Chiu, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 13 - +
  • [36] Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
    Kenichi Inoue
    Norikazu Masuda
    Hiroji Iwata
    Masato Takahashi
    Yoshinori Ito
    Yasuo Miyoshi
    Takahiro Nakayama
    Hirofumi Mukai
    Jan-Stefan van der Walt
    Joji Mori
    Sachi Sakaguchi
    Tsutomu Kawaguchi
    Yoshinori Tanizawa
    Antonio Llombart-Cussac
    George W. Sledge
    Masakazu Toi
    Breast Cancer, 2021, 28 : 1038 - 1050
  • [37] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
    Sawaki, Masataka
    Muramatsu, Yasuaki
    Togo, Kanae
    Iwata, Hiroji
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Safety and efficacy of ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
    De laurentiis, M.
    Mazza, M.
    Mansutti, M.
    Masetti, R.
    Ballatore, Z.
    Torrisi, R.
    Michelotti, A.
    Zambelli, A.
    Ferro, A.
    Generali, D.
    Vici, P.
    Coltelli, L.
    Fabi, A.
    Marchetti, P.
    Ballestrero, A.
    Spazzapan, S.
    Frassoldati, A.
    Sarobba, G.
    Grasso, D.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Ribociclib (RIB) plus letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
    Cottu, P. H.
    Ring, A.
    Marchetti, P.
    Cardoso, F.
    Salvador, J.
    Neven, P.
    Papazisis, K.
    Campone, M.
    Bachelot, T.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    De laurentiis, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S379 - S380
  • [40] Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib plus letrozole: Results from MONALEESA-2.
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Manson, Stephanie
    Sutradhar, Santosh C.
    Monaco, Mauricio
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345